It is no mystery to the pharmaceutical and biotech industry that between 2018 and 2023, several original reference biologics will be coming off patent. This clearly opens a significant window of opportunity for biosimilar manufacturers seeking to compete with the original biologics. George I’ons at Owen Mumford specifically focuses this article on analysing the different factors that will influence the uptake of new biosimilars and their advancing market share against original biologics.